期刊文献+

美他多辛治疗酒精性肝病的多中心、随机、双盲、安慰剂平行对照的临床研究 被引量:6

Capsule metadoxine in the treatment of alcoholic liver disease: A randomized, double-blind, placebocontrolled, multicenter study
分享 导出
摘要 目的观察美他多辛胶囊治疗酒精性肝病的临床疗效和安全性。方法采用多中心、随机、双盲、安慰剂平行对照的临床研究,254例酒精性肝病患者按1:1的比例随机进入试验组(美他多辛胶囊组)或安慰剂组。试验组:口服美他多辛胶囊每次500mg,每日3次;安慰剂组:口服美他多辛模拟胶囊每次2粒,每日3次。治疗疗程为6周,停药后2周随访。治疗期间患者每3周随访1次。治疗前、治疗第3、6周、停药后2周观察症状体征、肝肾功能、血常规、尿常规;治疗前、治疗第6周时对部分患者进行CT检查。对研究过程戒酒和不戒酒患者分层进行生物化学疗效评估。根据数据资料不同分别采用珊佥验、X^2检验、方差分析等方法进行统计学分析。结果254例患者进入本研究,试验组126例,安慰剂组128例。治疗6周后,试验组ALT、AST、γ-谷氨酰转肽酶中位数分别由治疗前的80.0、59.2、123.0U/L显著下降为治疗结束时的41.1、36.0、57.0U/L,其改善程度均分别显著优于安慰剂组,F值分别为2.689、2.567、3.097,P值均〈0.05,差异有统计学意义。戒酒患者治疗6周后,试验组血清生物化学改善的总有效率为82.8%,显著优于安慰剂组的55.7%,P=0.0000。不戒酒患者治疗6周后,试验组血清生物化学改善的总有效率为65.4%,安慰剂组为44.8%,P=0.1767,差异无统计学意义。治疗后试验组肝/脾CT比值显著提高(P=0.0023),但组间比较差异无统计学意义(P=0.6293)。试验组和安慰剂组不良反应发生率分别为1.6%和1.6%,两组间比较,P=1.000,差异无统计学意义。结论美他多辛胶囊可以安全、有效地治疗酒精性肝病。 Objective To evaluate the efficacy and safety of Capsule metadoxine in the treatment of alcoholic liver disease. Methods A randomized double blind multicenter placebo-controlled clinical study was performed to evaluate the therapeutic effectiveness and safety of capsule metadoxine. Patients in metadoxine group received capsule metadoxine 500mg tid po. Patients in placebo group received placebo 2 pillows tid po. The treatment duration was 6 weeks. Patients were followed up 2 weeks after the treatment. Patients were visited once every 3 weeks during the treatment period. Clinical symptoms and liver function were evaluated in all the patients before treatment, at week 3, week 6 and 2 weeks after therapy. CT scan was done in some patients before treatment and at the end point of therapy. Results 254 patients were recruited in the study, 126 in metadoxine group and 128 in placebo group. Median ALT, AST, GGT level in metadoxine group were decreased from 80.0 U/L, 59.2 U/L, 123.0 U/L (before treatment) to 41.1 U/L, 36.0 U/L, 57.0 U/L (after 6 weeks therapy).The improvement in liver function was more significant in metadoxine group than in placebo group (P 〈 0.05). For the patients who stopped drinking during the study, the total effective rate of improvement in liver function was 82.8% in metadoxine group, much higher than that in placebo group (55.7%, P = 0.0000). For the patients who did not stop drinking during the study, the total effective rate of improvement in liver function was 65.4% in metadoxine group, which is not significantly higher than that in placebo group (44.8%, P = 0.1767). The CT value ratio of liver to spleen was significantly improved in metadoxine group (P = 0.0023 ), and there was no significant difference between the two groups (P = 0.6293). The rate of adverse was 1.6% in both of groups. Conclusion Capsule metadoxine is an effective and safe treatment for alcoholic liver disease.
作者 茅益民 曾民德 厉有名 王炳元 尚佳 施瑞华 刘吉勇 陆伦根 曹爱平 MAO Yi-min, ZENG Min-de, LI You-ming, WANG Bing-yuan, SHANG Jia, SHI Rui-hua, LIU Ji-yong, LU Lun-gen, CAO Ai-ping(Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai 200001, China)
出处 《中华肝脏病杂志》 CAS CSCD 北大核心 2009年第3期213-216,共4页 Chinese Journal of Hepatology
关键词 肝疾病 酒精胜 治疗 随机对照试验 美他多辛 Liver disease, alcoholic Therapy Randomized controlled trials Metadoxin
作者简介 茅益民 男,41岁,副教授。Email:mym11968@yahoo.com.cn
  • 相关文献

参考文献7

  • 1厉有名,陈卫星,虞朝辉,乐敏,刘有恃,徐根云,季峰,李舒丹.浙江省酒精性肝病流行病学调查概况[J].中华肝脏病杂志,2003,11(11):647-649. 被引量:141
  • 2茅益民,曾民德,陆伦根,王炳元,尚佳,施瑞华,刘吉勇,樊微,魏良洲,王青,汪素文,周海洋.美他多辛片治疗酒精性肝病的多中心、随机、双盲、安慰剂平行对照临床研究[J].肝脏,2006,11(5):303-306. 被引量:9
  • 3Shpilenya LS, Muzychenko AP, Gasbarrini G, et al. Metadoxine in acute alcohol intoxication: a double-blind, randomized, placebo-controlled study. Alcohol Clin Exp Res, 2002, 26: 340-346. 被引量:1
  • 4酒精性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):164-166. 被引量:260
  • 5Calabrese V, Calderone A, Ragusa N, et al. Effects of Metadoxine on cellular status of glutathione and of enzymatic defence system following acute ethanol intoxication in rats. Drugs Exp Clin Res, 1996, 22: 17-24. 被引量:1
  • 6Gutiirrez-Ruiz MC, Bucio L, Correa A, et al. Metadoxine prevents damage produced by ethanol and acetaldehyde in hepatocyte and hepatic stellate cells in culture. Pharmacol Res, 2001, 44: 431-436. 被引量:1
  • 7Caballera J, Pares A, Brfi C, et al. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver. J Hepatol, 1998, 28: 54-60. 被引量:1

二级参考文献26

  • 1胡国平 ,刘凯 ,赵连三 .多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量:98
  • 2邱德凯.重视对酒精性肝病的防治[J].中华消化杂志,1993,13:126-126. 被引量:44
  • 3Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. Gut, 1997, 41: 845-850. 被引量:1
  • 4袁平戈 周卫平.酒精性肝病及肝纤维化学术研讨会纪要[J].肝脏病杂志,1995,3:196-196. 被引量:10
  • 5Lok AS,McMahon B J; Practice Guidelines Committee,American Association for the Study of Liver Diseases (AASLD).Chronic hepatitis B:update of recommendations.Hepatology,2004,39:857-861. 被引量:1
  • 6Sanyal AJ.American Gastroenterological Association technical review on nonalcoholic fatty liver disease.Gastroenterology,2002,123:1705-1725. 被引量:1
  • 7Graif M,Yanuka M,Baraz M,et al.Quantitative estimation of attenuation in ultrasound video images:correlation with histology in diffuse liver disease.Invest Radiol,2000,35:319-324. 被引量:1
  • 8Ataseven H,Yildrim MH,Yalniz M,et al.Correlation between computerized tomographic findings and histopathologic grade/stage in non-alcoholic steatohepatitis.J Hepatol,2003,38(Suppl 2):A4177. 被引量:1
  • 9Farrell GC,George J,Pauline de la M.Hall,et al,eds.Fatty liver diseas:NASH and related disorders.Oxford:Blackwell Publishing,2005.159-207. 被引量:1
  • 10McCullough AJ,O'Connor JF.Alcoholic liver disease:proposed recommendations for the American College of Gastroenterology.Am J Gastroenterol,1998,93:2022-2036. 被引量:1

共引文献386

同被引文献42

引证文献6

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈